Quarterly Results

202601 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ2 FY25-26Q2 FY24-25Change %FY24-25FY23-24Change %
Total Revenue14,478.3113,291.398.9352,578.4448,496.858.42
Expenses9,951.269,352.436.4037,984.6035,968.045.61
Other Income469.92354.0032.751,965.041,354.1945.11
Operating Profit569.78423.1734.6516,558.8813,883.0019.27
Depreciation729.50625.9116.552,575.392,556.640.73
Interest99.8669.1744.37231.36238.47-2.98
Profit Before Tax4,155.473,604.5415.2813,752.1311,087.8924.03
Tax1,030.52567.2181.682,772.031,439.4592.58
Net Profit3,117.953,040.162.5610,980.109,648.4413.80
CategoryQ2 FY25-26Q1 FY25-26Change %
Total Revenue14,478.3113,851.404.53
Expenses9,951.2610,367.74-4.02
Other Income469.92464.461.18
Operating Profit569.78539.265.66
Depreciation729.50700.554.13
Interest99.8674.8033.50
Profit Before Tax4,155.473,163.0231.38
Tax1,030.52870.1518.43
Net Profit3,117.953,096.630.69

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Innovative portfolio likely to maintain growth momentum for Sun Pharma

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxcyt to anchor next phase

Updated On: 06 Nov 2025 | 6:42 PM IST

Sun Pharma Q2 net profit rises 2.5% to ₹3,118 crore on India, EM growth

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

Updated On: 05 Nov 2025 | 5:49 PM IST

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Updated On: 04 Nov 2025 | 12:42 PM IST

Stocks to buy today: Analyst bets on Sun Pharma, Indus Towers; check why

Shrikant Chouhan, Head of Equity Research at Kotak Securities, has recommended buying shares of Sun Pharma and Indus Towers today

Updated On: 28 Oct 2025 | 7:28 AM IST

Churning portfolio ahead of Diwali? Ambit lists top 10 'winning' stocks

Ambit analysts see HDFC Bank benefiting from accelerating credit growth, normalisation in cost of funds, and focus on high-yield segments like MSME, gold, and unsecured retail loans.

Updated On: 09 Oct 2025 | 11:20 AM IST

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Updated On: 09 Oct 2025 | 11:24 AM IST

Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Updated On: 01 Oct 2025 | 9:59 AM IST

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Updated On: 28 Sep 2025 | 1:48 PM IST

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Updated On: 26 Sep 2025 | 9:13 AM IST

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Updated On: 26 Sep 2025 | 10:08 AM IST
More